Get the Stockscreener App
14.77
20.63%
-3.84
After Hours:
14.89
0.12
+0.81%
Neogenomics Inc stock is traded at $14.77, with a volume of 2.55M.
It is down -20.63% in the last 24 hours and down -19.86% over the past month.
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
See More
Previous Close:
$18.61
Open:
$17.75
24h Volume:
2.55M
Relative Volume:
3.73
Market Cap:
$1.90B
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-23.82
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
-13.02%
1M Performance:
-19.86%
6M Performance:
+9.25%
1Y Performance:
-7.51%
1-Day Range:
$14.51
$17.75
1-Week Range:
$14.51
$19.11
52-Week Range:
$12.77
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
14.77 | 1.90B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
542.31 | 207.43B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
235.07 | 169.79B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
137.47 | 39.26B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
203.27 | 36.89B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
418.05 | 34.23B | 3.84B | 866.24M | 792.60M | 10.37 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
NeoGenomics announces CEO succession plan - Gulfshore Business
NeoGenomics Shares Fall on CEO's Plan to Retire - MarketWatch
NeoGenomics' (NEO) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
NeoGenomics (NEO) Shares Cross Below 200 DMA - Nasdaq
NeoGenomics Shares Are Falling Today: What's Going On? - Benzinga
NeoGenomics (NASDAQ:NEO) Shares Gap DownTime to Sell? - MarketBeat
NeoGenomics CEO steps down, shares fall 17% By Investing.com - Investing.com Canada
NeoGenomics (NASDAQ:NEO) Releases FY 2024 Earnings Guidance - MarketBeat
NeoGenomics (NEO) CEO Chris Smith to retire - StreetInsider.com
NeoGenomics, Inc. Reaffirms Earnings Guidance for Full Year Ended December 31, 2024 - Marketscreener.com
NeoGenomics Appoints Tony Zook As CEO - citybiz
NeoGenomics CEO Chris Smith to Retire; Tony Zook to Take Helm - MarketWatch
NeoGenomics Announces CEO Transition and Leadership Change - TipRanks
NeoGenomics Announces Chief Executive Officer Succession - The Bakersfield Californian
Neogenomics, Announces Retirement of Chris Smith as Board Member, Effective April 1, 2025 - Marketscreener.com
Leerink Partnrs Weighs in on NeoGenomics FY2024 Earnings - MarketBeat
NeoGenomics (NASDAQ:NEO) Sets New 12-Month HighShould You Buy? - MarketBeat
NeoGenomics stock hits 52-week high at $19.01 amid growth By Investing.com - Investing.com South Africa
NeoGenomics stock hits 52-week high at $19.01 amid growth - Investing.com
NeoGenomics CEO to Present Strategic Vision at J.P. Morgan Healthcare Conference - StockTitan
NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Bakersfield Californian
NeoGenomics (NEO) Upgraded to Buy: Here's Why - MSN
The past three years for NeoGenomics (NASDAQ:NEO) investors has not been profitable - Simply Wall St
IBD Rating Upgrades: NeoGenomics Flashes Improved Price Strength - MSN
NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
NeoGenomics, Inc. (NASDAQ:NEO) Shares Acquired by Geode Capital Management LLC - MarketBeat
Franklin Resources Inc. Has $28.23 Million Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
NeoGenomics, Inc. (NASDAQ:NEO) Shares Bought by State Street Corp - MarketBeat
Natera expands lawsuit against NeoGenomics over RaDaR test By Investing.com - Investing.com Canada
Natera expands lawsuit against NeoGenomics over RaDaR test - Investing.com India
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics - Business Wire
Bank of America Raises NeoGenomics (NASDAQ:NEO) Price Target to $19.00 - Defense World
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma - BioSpace
BNP Paribas Financial Markets Boosts Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
NeoGenomics' Breakthrough Study Shows Promise in Early Melanoma Detection Using RaDaR® Technology - StockTitan
Evaluating NeoGenomics: Insights From 4 Financial Analysts - Benzinga
NeoGenomics Getting Closer To Key Technical Measure - MSN
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting - Business Wire
Charles Schwab Investment Management Inc. Acquires 57,677 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
NeoGenomics Inc (NEO) Trading 4.33% Higher on Dec 6 - GuruFocus.com
ConcertAI and NeoGenomics announce AI software-as-a-service solution for hematology clinical research - The Cancer Letter
Edgestream Partners L.P. Sells 94,791 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research - Business Wire
ConcertAI, NeoGenomics Launch Groundbreaking 370,000-Patient Hematology Research Platform - StockTitan
NeoGenomics, Inc. (NASDAQ:NEO) Shares Purchased by Bellevue Group AG - MarketBeat
NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Mutual of America Capital Management LLC Sells 1,716 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
Algert Global LLC Has $1.18 Million Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
Natixis Advisors LLC Buys 11,936 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
Loomis Sayles & Co. L P Purchases Shares of 1,207,290 NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
(NEO) Investment Analysis - Stock Traders Daily
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
1.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):